This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vertex Makes CEO Change Amidst Efforts to Diversify Beyond Hepatitis C

Stocks in this article: VRTX GILD VRUS ABT

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX) CEO Matt Emmens is stepping down in February, just three years after taking the post at the biopharmaceutical firm known best for its recently launched hepatitis C drug Incivek.

Jeff Leiden, a former Abbott (ABT) top executive and current Vertex board member, will take over as Vertex's CEO, the company said in a statement Thursday.

Vertex's CEO swap comes as questions swirl around the company’s future. Incivek was one of the most successful new drug launches in history and helped Vertex reach profitability for the first time. But Incivek's long-term commercial potential is now threatened by newer, more potent hepatitis C therapies working their way towards the market. Most prominently, these new hepatitis C drugs include those Gilead Sciences (GILD) just acquired by paying $11 billion for Pharmasset (VRUS).

As a result, Vertex's stock price, which reached $58 last May right before Incivek was approved, has sunk to around $30 and is down about 14% this year. Vertex is trying to change investor perceptions of the company as one that is solely focused on hepatitis C. Important to this effort to help Vertex diversify will be the expected approval and launch next spring of a new cystic fibrosis drug known as Kalydeco.

Emmens came out of retirement from Shire to take the Vertex CEO job and help the company build out a commercial team that could sell Incivek and Kalydeco. Prior to his arrival, Vertex had no approved drugs to sell.

"I've been talking to the board about succession since I arrived here," says Emmens, whose three-year employment contract ends in May. "Many CEOs stay too long. I know my skill set and what I was supposed to do at Vertex. Now, it's time to hand over the controls to Jeff."

Sanford Bernstein biotech analyst Geoff Porges says many investors who know Vertex well are not surprised Emmens decided to leave once his three-year contract ended. The timing of the transition is a bit earlier than expected, however.

"The timing of the announcement may be a bit unsettling to investors given the Incivek questions and the upcoming Kalydeco launch, but Leiden is really smart and it will be to Vertex's advantage to have a guy with a science and business background in charge."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs